Are gender differences important for the clinical effects of antidepressants?

American Journal of Psychiatry

Volumn 160, Issue 9, 2003, Pages 1643-1650

  Hildebrandt, Malene Grubbe ^a   Steyerberg, Ewout Willem ^a   Stage, Kurt Bjerregaard ^a   Passchier, Jan ^a   Kragh Soerensen, Per ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; MOCLOBEMIDE; PAROXETINE; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CONTROLLED STUDY; FEMALE; HAMILTON SCALE; HUMAN; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MELANCHOLIA; NONPARAMETRIC TEST; OUTCOMES RESEARCH; PATIENT PARTICIPATION; PRIORITY JOURNAL; RATING SCALE; REMISSION; SEX DIFFERENCE; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DOUBLE BLIND PROCEDURE; METABOLISM; PATIENT; PHARMACOGENETICS; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLOMIPRAMINE; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; PATIENT DROPOUTS; PHARMACOGENETICS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 0642282678     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.9.1643     Document Type: Article

References (32)

1. Gater R, Tansella M, Korten A, Tiemens BG, Mavreas VG, Olatawura MO: Sex differences in the prevalence and detection of depressive and anxiety disorders in general health care settings: report from the World Health Organization Collaborative Study on Psychological Problems in General Health Care. Arch Gen Psychiatry 1998; 55:405-413
2. Weissman MM, Klerman GL: Sex differences and the epidemiology of depression. Arch Gen Psychiatry 1977; 34:98-111
3. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lepine JP, Newman SC, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen H, Yeh EK: Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276:293-299
4. Yonkers KA, Brawman-Mintzer O: The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry 2002; 63:610-615
5. Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs: notice. Federal Register 1993; 58:39406-39416
6. Davidson J, Pelton S: Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986; 17:87-95
7. Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison W, Keller MB: Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157:1445-1452
8. Quitkin FM, Stewart JW, McGrath PJ, Taylor BP, Tisminetzky MS, Petkova E, Ma YG, Klein DF: Are there differences between women's and men's antidepressant responses? Am J Psychiatry 2002; 157:1848-1854
9. Hamilton JA, Grant M, Jensvold MF: Sex and treatment of depressions: when does it matter? in Psychopharmacology and Women: Sex, Gender and Hormones. Edited by Jensvold MF, Halbreich U, Hamilton JA. Washington, DC, American Psychiatric Press, 1996, pp 241-260
10. Frackiewicz EJ, Sramek JJ, Cutler NR: Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann Pharmacother 2000; 34:80-88
11. Danish University Antidepressant Group: Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology (Berl) 1986; 90:131-138
12. Danish University Antidepressant Group: Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18:289-299
13. Danish University Antidepressant Group: Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1993; 28:105-116
14. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
15. Bech P, Kastrup M, Rafaelsen OJ: Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl 1986; 326:1-37
16. Bech P, Allerup P, Reisby N, Gram LF: Assessment of symptom change from improvement curves on the Hamilton depression scale in trials with antidepressants. Psychopharmacology (Berl) 1984; 84:276-281
17. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334:1-100
18. Bech P, Gjerris A, Andersen J, Bojholm S, Kramp P, Bolwig TG, Kastrup M, Clemmesen L, Rafaelsen OJ: The Melancholia Scale and the Newcastle Scales: item-combinations and inter-observer reliability. Br J Psychiatry 1983; 143:58-63
19. Mullaney JA: The validity of two Newcastle Diagnostic Scales in the affective disorders: bimodality and other correlates. J Affect Disord 1985; 9:239-247
20. Bartko JJ, Carpenter WT Jr: On the methods and theory of reliability. J Nerv Ment Dis 1976; 163:307-317
21. Nielsen KK, Brosen K: High-performance liquid chromatography of clomipramine and metabolites in human plasma and urine. Ther Drug Monit 1993; 15:122-128
22. Kornstein SG: Gender differences in depression: implications for treatment. J Clin Psychiatry 1997; 58(suppl 15):12-18
23. Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF: Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 1996; 40:1017-1020
24. Quitkin FM, Stewart JW, McGrath PJ, Tricamo E, Rabkin JG, Ocepek-Welikson K, Nunes E, Harrison W, Klein DF: Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl 1993; 21:30-34
25. Roose SP, Glassman AH, Attia E, Woodring S: Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151:1735-1739
26. Parker G: "New" and "old" antidepressants: all equal in the eyes of the lore? Br J Psychiatry 2001; 179:95-96
27. Stage KB, Bech P, Gram LF, Kragh-Sorensen P, Rosenberg C, Ohrberg S (Danish University Antidepressant Group): Are in-patient depressives more often of the melancholic subtype? Acta Psychiatr Scand 1998; 98:432-436
28. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder (Revision). Am J Psychiatry 2000; 157(April suppl)
29. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Garrone G: Clomipramine metabolism: model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet 1990; 19:241-255
30. Grossman MI, Kirsner JB, Gillespie IE: Basal and histolog-stimulated gastric secretion in control subjects and in patients with peptic ulcer or gastric cancer. Gastroenterology 1963; 45:14-26
31. Wald A, Van Thiel DH, Hoechstetter L, Gavaler JS, Egler KM, Verm R, Scott L, Lester R: Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology 1981; 80:1497-1500
32. Yonkers KA, Kando JC, Cole JO, Blumenthal S: Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992; 149:587-595